Clinical Trial

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

Study acronym: CSG-1827-101
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy, or without available standard or curative therapy.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2026-06-30 -> 2026-03-18 2026-07-16
Trial Details
NCT Number NCT06076291
Lead Sponsor Hangzhou Sumgen Biotech Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 122 participants
Start Date 2023-09-27
Primary Completion 2026-03-18 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15